iPierian names new president and chief scientific officer
Feb 24, 2010 (Datamonitor via COMTEX) --
iPierian, a biopharmaceutical company, has appointed Michael Venuti as its new president and chief scientific officer.
Prior to joining iPierian, Dr Venuti served as CEO and member of the board of directors of BioSeek. He previously served as CEO and member of the board of directors of Discovery Partners International, a small molecule-based drug discovery services company. Dr Venuti led the merger of Discovery Partners into Infinity Pharmaceuticals in 2006.
From 2001 through 2005, he held positions as senior vice president of business development and pharmacogenomics, and senior vice president of research and preclinical development at Celera Genomics, and served as the general manager of Celera South San Francisco. He served as senior vice president, research and preclinical development, at Axys Pharmaceuticals prior to its acquisition by Celera.
John Walker, chief executive officer of iPierian, said: "A major goal for iPierian over the next five years is to develop drug candidates, both on its own and through partnerships, based on the application of cellular reprogramming to the discovery process. Mike's expertise using cell-based human disease models will be instrumental as we apply our induced pluripotent stem cell technology to find more effective therapeutics for patients.
"We will look to his 25 years of experience leading biotechnology and pharmaceutical companies and establishing large-scale discovery and development collaborations, to help us advance our proprietary neurodegenerative programs and develop partnerships in broad therapeutic areas such as metabolic disease. His efforts will complement those of our vice president of research and chief technology officer Dr Berta Strulovici, who will continue to lead and direct our research programs."
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To TMCnet.com's Homepage ]